Do pharmacological and interventional approaches prevent or treat microvascular obstruction in patients with STEMI undergoing primary PCI?
Current evidence for pharmacological and interventional strategies to treat microvascular obstruction in STEMI remains inconclusive, highlighting the need for standardized, contemporary trials.
Microvascular obstruction (MVO) accounts for up to 50% of patients diagnosed with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The pathogenesis is multifactorial and includes myocardial ischemia, distal embolization, and ischemia-reperfusion injury, in a context of individual susceptibility. Its occurrence has been related to adverse outcomes. Despite an extensive body of research, no single pharmacological or interventional strategy has proven effectiveness. The inconclusive nature of the evidence can be attributed to lack of standardization among studies in terms of drugs used and their dosage, the variability in study designs, and the fact that available studies performed a decade ago feature reperfusion strategies and drugs used that differ significantly from the current standard of care. In this context, our review aims to discuss the pharmacological and interventional approaches to MVO.
Occhipinti et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: